National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No. 7) (PB 55 of 2014) (Cth)

PB 55 of 2014

National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No. 7)

National Health Act 1953

___________________________________________________________________________

I, KIM BESSELL, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Amendment Instrument under subsections 100(1) and 100(2) of the National Health Act 1953.

Dated  24 July 2014

KIM BESSELL

Assistant Secretary

Pharmaceutical Access Branch

Pharmaceutical Benefits Division

Department of Health

___________________________________________________________________________

1       Name of Instrument

(1)This Instrument is the National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No.7).

(2)This Instrument may also be cited as PB 55 of 2014.

2              Commencement

This Instrument commences on 1 August 2014.

3              Amendments to PB 116 of 2010

Schedule 1 amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010).

Schedule 1       Amendments

1. Schedule 1, after entry for Epoprostenol in the form Powder for I.V. infusion, 500 micrograms (as sodium) infusion administration set

insert in the columns in the order indicated:

Powder for I.V. infusion 500 micrograms (as sodium) Injection Veletri AT EMP C3167 C4013 C4014 See Note 1 See Note 2 D

1. Schedule 1, after entry for Epoprostenol in the form Powder for I.V. infusion, 1.5 mg (as sodium) infusion administration set

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Powder for I.V. infusion 1.5 mg (as sodium) Injection Veletri AT EMP C3167 C4013 C4014 See Note 1 See Note 2 D

1. Schedule 1, entry for Omalizumab

Omalizumab	Injection 75 mg in 0.5 mL single dose pre-filled syringe	Injection	Xolair	NV	EMP	C3740 C3742 C3822	See Note 1	See Note 2	D
Injection 150 mg in 1 mL single dose pre-filled syringe	Injection	Xolair	NV	EMP	C3740 C3742 C3822	See Note 1	See Note 2	D
Powder for Injection 150 mg with Diluent	Injection	Xolair	NV	EMP	C3740 C3742 C3822	See Note 1	See Note 2	D

Substitute:

1. Schedule 1, entry for Sildenafil

APO-Sildenafil PHT TX EMP C3174 C3175 C4017 C4018 See Note 1 See Note 2 D

(a)   insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

(b)   insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Sildenafil Sandoz PHT 20 SZ EMP C3174 C3175 C4017 C4018 See Note 1 See Note 2 D

1. Schedule 1, entry for Tacrolimus in the form Capsule 0.5 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Pharmacor Tacrolimus 0.5 CR EMP C1654 C3328 200 5 C

1. Schedule 1, entry for Tacrolimus in the form Capsule 1 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Pharmacor Tacrolimus 1 CR EMP C1654 C3328 200 5 C

1. Schedule 1, entry for Tacrolimus in the form Capsule 5 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Pharmacor Tacrolimus 5 CR EMP C1654 C3328 100 5 C